{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:56:21Z","timestamp":1791078981485,"version":"4.1.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamadermatol.2018.3679","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T20:18:13Z","timestamp":1540585093000},"page":"1424","source":"Crossref","is-referenced-by-count":11,"title":["Association of <i>APOA5<\/i> and <i>APOC3<\/i> Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene"],"prefix":"10.1001","volume":"154","author":[{"given":"Irene","family":"Cabello","sequence":"first","affiliation":[{"name":"Cardiovascular Risk Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Alia","sequence":"additional","affiliation":[{"name":"Clinical Genetics Laboratory, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[{"name":"Cardiovascular Risk Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Muniesa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fernandez-de-Misa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Nuestra Se\u00f1ora de la Candelaria, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerai","family":"Pe\u00f1ate","sequence":"additional","affiliation":[{"name":"Dermatology Department, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Morillo","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Perez-Farriols","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Estrach","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Cl\u00ednic, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Izu","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario de Basurto, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital del Mar, IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Cervig\u00f3n","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Nuestra Se\u00f1ora del Prado, Talavera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Ortiz-Brugues","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Arnau de Vilanova, Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Servitje","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi180056r1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjd.2012.168.issue-1","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"doi180056r2","first-page":"367","article-title":"The utility of bexarotene in mycosis fungoides and S\u00e9zary syndrome.","volume":"8","author":"Panchal","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"6","key":"doi180056r3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/bjd.2003.149.issue-6","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"issue":"13","key":"doi180056r4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1517\/14656566.2013.810718","article-title":"Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.","volume":"14","author":"Qu\u00e9reux","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"doi180056r5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome.","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"issue":"8","key":"doi180056r6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ajh.v89.8","article-title":"Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management.","volume":"89","author":"Wilcox","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"doi180056r7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.2006.155.issue-2","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi180056r8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/MPA.0b013e31816074a1","article-title":"Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia.","volume":"37","author":"Lloret Linares","year":"2008","journal-title":"Pancreas"},{"issue":"3","key":"doi180056r9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ced.2017.42.issue-3","article-title":"Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.","volume":"42","author":"Cabello","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"doi180056r10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the genomic era: a new paradigm.","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr Rev"},{"issue":"36","key":"doi180056r11","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.2174\/0929867311209066163","article-title":"Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature.","volume":"19","author":"Melegh","year":"2012","journal-title":"Curr Med Chem"},{"issue":"2","key":"doi180056r12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides.","volume":"52","author":"Johansen","year":"2011","journal-title":"J Lipid Res"},{"key":"doi180056r13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12944-016-0251-2","article-title":"Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain.","volume":"15","author":"Lamiquiz-Moneo","year":"2016","journal-title":"Lipids Health Dis"},{"key":"doi180056r14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2350-11-120","article-title":"Association of the apolipoprotein A5 gene -1131 T&gt;C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects.","volume":"11","author":"Zhao","year":"2010","journal-title":"BMC Med Genet"},{"issue":"8","key":"doi180056r15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.biopha.2011.04.003","article-title":"Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies.","volume":"65","author":"Dergunov","year":"2011","journal-title":"Biomed Pharmacother"},{"issue":"20","key":"doi180056r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"doi180056r17","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"doi180056r18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"doi180056r20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.2009.160.issue-6","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome.","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi180056r21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"24","key":"doi180056r22","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1093\/hmg\/11.24.3031","article-title":"Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.","volume":"11","author":"Pennacchio","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"24","key":"doi180056r23","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1093\/hmg\/11.24.3039","article-title":"Relative contribution of variation within the APOC3\/A4\/A5 gene cluster in determining plasma triglycerides.","volume":"11","author":"Talmud","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"20","key":"doi180056r24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1157\/13121105","article-title":"Apolipoprotein A5 gene: association with triglyceride metabolism and cardiovascular disease","volume":"130","author":"Oliveira Sousa","year":"2008","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"doi180056r25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2012.06.002","article-title":"Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T&gt;C polymorphism and fasting triglyceride levels.","volume":"7","author":"Kim","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"2","key":"doi180056r26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/FPC.0b013e32831e030e","article-title":"Pharmacogenetic association of the APOA1\/C3\/A4\/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.","volume":"19","author":"Liu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"doi180056r27","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1161\/ATVBAHA.107.140103","article-title":"Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.","volume":"27","author":"Lai","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"doi180056r28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/ATVBAHA.107.144980","article-title":"Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.","volume":"27","author":"Hegele","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10094","key":"doi180056r29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"doi180056r19","unstructured":"ExAC Browser (Beta)\/Exome Aggregation Consortium website. http:\/\/exac.broadinstitute.org\/. Accessed September 21, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2709120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T16:03:08Z","timestamp":1544630588000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.3679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.3679","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}